mRNA therapy for relapsed autoimmune diseases
Part of Immune system & allergy clinical trials.
This early-phase trial tests an mRNA drug that targets CD19 and BCMA proteins. It aims to treat autoimmune diseases like lupus that have come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have a relapsed or refractory autoimmune disease (e.g., lupus) that has not responded well to other treatments
- You are in fairly good health, able to care for yourself (KPS score > 60)
- Your life expectancy is more than 6 months
- If you could become pregnant, you agree to use effective birth control during the study and 30 days after stopping the drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA treatment that targets a protein called CD19 on immune cells. It may help people with severe autoimmune diseases like lupus, ITP, or AIHA when other treatments haven't worked.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a new type of cell therapy (SCAR02) that targets two proteins on immune cells to help calm down overactive autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis. It may be an option if standard treatments haven't worked well enough.
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.